Safety of the combination of chloroquine healthy adult men with G6PD deficiency Faso
Safety of the combination of chloroquine healthy adult men with G6PD deficiency Faso
复制标题
DOI：
10.1111/j.1365-3156.2004.01356.x
复制
发表时间：
2005-01-01
影响因子：
3.3
通讯作者：
Müller, O
中科院分区：
文献类型：
--
作者：
Mandi, G;Witte, S;Müller, O
撒哈拉以南非洲地区迫切需要针对恶性疟疾的新药物组合，既有效又负担得起。众所周知的药物氯喹（CQ）和亚甲蓝（MB）的组合是一种很有前途的新疗法。然而，有人担心 MB 可能会导致葡萄糖-6-磷酸脱氢酶 (G6PD) 缺乏症患者发生溶血，这种情况在疟疾流行地区很常见。在此背景下，布基纳法索西北部努纳地区医院对 74 名 G6PD 缺乏但其他方面健康的成年男性进行了为期 3 天的口服治疗，总计 1500 毫克 CQ 和 780 毫克 MB。研究参与者没有发生溶血，血红蛋白水平保持稳定甚至上升，药物治疗方案耐受性良好。因此，MB 的标准剂量对于 G6PD 缺乏的非洲人群（主要是 III 类 G6PD 缺乏）似乎是安全的。
New drug combinations against falciparum malaria which are both effective and affordable for Sub-Saharan African populations are urgently needed. The combination of the well-known drugs chloroquine (CQ) and methylene blue (MB) is such a promising new regimen. However, there is some concern that MB could cause development of haemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, a condition which is prevalent in malaria-endemic regions. Against this background, 74 G6PD-deficient but otherwise healthy adult men were given a 3-day oral regimen of a total of 1500 mg CQ and 780 mg MB in the District Hospital of Nouna in northwestern Burkina Faso. Haemolysis did not occur, haemoglobin levels remained stable or even rose in the study participants, and the drug regimen was well tolerated. Therefore, standard dosages of MB appear to be safe in G6PD-deficient African populations with predominantly class III G6PD deficiency.